Lutein + Zeaxanthin showed an approximate 20% beneficial effect vs beta-carotene, as well as no increased risk of lung cancer in patients who were former and current smokers.1
20 Years of AMD Leadership
Related Eye Disease
NEI researchers concluded their first
five-year clinical Age Related Eye Disease
Study participants ages 55
to 80 years, with and
Reduced risk of moderate
vision loss after five years.
Reduction in risk of AMD
progression in those with
moderate to advanced
continued effects at
study follow-up in 2006.
2nd Age Related Eye
Based on new learnings around AMD, the
NEI researchers sought to improve the
original AREDS formula.
The result was an updated formula that replaced beta-carotene with lutein and zeaxanthin, since new research suggested an association between beta-carotene and an increase in the risk of lung cancer among those with a history of smoking.2
Study participants ages 50
to 85, with AMD.
Clinical centers across the
Length of AREDS2 study.
Reduced risk of
progressing to advanced
AMD, compared to
patients taking the
- No clinically statistically significant differences in AEs between treatment groups. Post-hoc subgroup analysis
- Johnson EJ. Curr Opin Clin Nutr Metab Care. 2010;13(1):28-33
1. No clinically statistically significant differences in AEs between treatment groups. Post-hoc subgroup analysis
2. Johnson EJ. Curr Opin Clin Nutr Metab Care. 2010;13(1):28-33
The NEI publishes the results of its 10 Year Follow-on
study1, using Bausch + Lomb’s PreserVision®
AREDS 2 Formula Eye Vitamins in the last 5
years of study.
The NEI’s AREDS2 10 year Follow-on study
further validated the original findings about
the AREDS2 formulation with 80mg of zinc.
The study also provided support for the
continued benefit of lutein and zeaxanthin vs.
Eyes in the NEI AREDS2 10
year follow-on study
Reduction in progression
to late AMD
Reduction in progression
to neovascular AMD
10 Years of sustained
- Chew, Emily Y., et al. JAMA Ophthalmol. Published online June 2, 2022. doi:10.1001/jamaophthalmol.2022.1640
The NEI recommends taking a vitamin formula that contains the exact nutrients based on the AREDS2 study for helping to reduce the risk of progression in moderate to advanced AMD.
|Nutrient||Amount (per day)||Percent Daily Value|
|Vitamin C||500 mg||556%|
|Vitamin E||180 mg||1200%|
* Percent Daily Values (DV) Based on a 2000-calorie diet
**Daily value not established
No significant side effects were observed in patients who received a formula with 80 mg zinc per day.
Therefore, the NEI continues to recommend 80mg zinc per the results of the AREDS2 10 year follow-on study.
Recent data indicates no statistical beneficial effect in EPA+DHA towards reducing the risk of progression to late AMD in the AREDS2 formulation.
- Chew, E.Y, et al. 2022. The Long-term effects of adding Lutein-Zeaxanthin and Omega-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration. [Unpublished Manuscript] The AREDS2 Research Group/National Eye Institute.